LOGIN
WCO-IOF 2016: Lasofoxifene, raloxifene, and placebo for BMD in postmenopausal women
May 2016
WCO-IOF 2016: Lasofoxifene, raloxifene, and placebo for BMD in postmenopausal women
Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A
The phase 3 comparison of raloxifene and lasofoxifene (CORAL) trial: changes in bone markers and bone mineral density
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
Synopsis
540 postmenopausal women with normal to low bone mineral density were randomized to 24 months of treatment with either lasofoxifene 0.25mg/day, raloxifene 60mg/day, or daily placebo. The purpose of this study was to compare changes in bone mineral density and bone turnover markers between groups after 24 months of treatment. Change in bone mineral density of the lumbar spine and total hip were rep...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.